bioMérieux Launches VIDAS® NT-proBNP, an Aid for Diagnosis and Prognosis of Heart Failure
Mon, 01/10/2007
bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics.
Early Diagnosis of Sepsis: bioMérieux presents new Sepsis Handbook at International Sepsis Forum
Wed, 26/09/2007
bioMérieux, a global leader in the field of in vitro diagnostics, today announces the launch of the “Sepsis Handbook”. This comprehensive book, produced by bioMérieux Editions, will be presented in a special preview at the International Sepsis Forum (ISF) held in Paris (Institut Pasteur), September 26-29, 2007.
bioMérieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for New Breast Cancer Treatment
Mon, 17/09/2007
bioMérieux and Ipsen announce today that they have signed an agreement by which bioMérieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMérieux and Ipsen.
bioMérieux launches the first automated detection test for Clostridium difficile A and B toxins
Tue, 24/07/2007
A new, rapid, and effective solution in the fight against hospital-acquired (nosocomial)infections. bioMérieux, a world leader in the field of in vitro diagnostics, (Euronext : BIM) has just launched VIDAS® C. difficile Toxin A&B, a test for the detection of a bacterium responsible for fatal nosocomial epidemics in Canada, the United States and, more recently, in Europe.
Healthcare-Associated Infections : First World Forum on a critical public health issue
Wed, 30/05/2007
bioMérieux organizes the First World Forum on Healthcare-Associated Infections (HAI). This Forum will bring together around fifty international experts at the Mérieux Foundation Conference Center (Les Pensières, Veyrier-du-Lac, France) from June 4th to 5th 2007.
